share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股SEC公告 ·  10/02 13:34

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares on 10/02/2024, as per the latest filing. These shares, with an aggregate market value of $123,200, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 190,000 shares were sold for gross proceeds of $1,334,100.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 20,000 Class A shares on 10/02/2024, as per the latest filing. These shares, with an aggregate market value of $123,200, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This planned sale follows a series of transactions over the past three months, where a total of 190,000 shares were sold for gross proceeds of $1,334,100.
Recursion Pharmaceuticals, Inc.董事兼總經理Christopher Gibson計劃於2024年10月2日賣出20,000股A類股份,根據最新提交的文件。這些股份的市值總計爲123,200美元,最初是作爲創始人股份於2016年09月01日從發行方獲得作爲補償的。這一計劃的出售是在過去三個月中一系列交易的後續,共賣出了19萬股,總收益爲1,334,100美元。
Recursion Pharmaceuticals, Inc.董事兼總經理Christopher Gibson計劃於2024年10月2日賣出20,000股A類股份,根據最新提交的文件。這些股份的市值總計爲123,200美元,最初是作爲創始人股份於2016年09月01日從發行方獲得作爲補償的。這一計劃的出售是在過去三個月中一系列交易的後續,共賣出了19萬股,總收益爲1,334,100美元。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息